Understand the source comparison
Does VIP Help Inflammation Research? — Critical Comparison
Rheumatoid Arthritis VPAC1 receptor activation on synovial macrophages ↓ TNF-alpha, ↓ IL-6, ↑ IL-10 50% reduction in joint inflammation scores VIP shows promise in autoimmune arthritis models but requires dose optimization for sustained effect Inflammatory Bow
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Rheumatoid Arthritis
- VPAC1 receptor activation on synovial macrophages
- ↓ TNF-alpha, ↓ IL-6, ↑ IL-10
- 50% reduction in joint inflammation scores
- VIP shows promise in autoimmune arthritis models but requires dose optimization for sustained effect
- Inflammatory Bowel Disease
- Epithelial barrier strengthening + IL-10 induction
- ↓ IFN-gamma, ↓ IL-17, ↑ IL-10
- 55% reduction in DSS colitis severity
- Strong preclinical data; VIP's dual barrier + immune effect is mechanistically unique
- Sepsis / Endotoxemia
- NF-kappaB inhibition + HMGB1 suppression
- ↓ TNF-alpha, ↓ IL-6, ↓ HMGB1
- 50% mortality reduction in CLP models
- VIP's timing-dependent efficacy makes it a viable adjunct therapy target for septic shock
- Multiple Sclerosis (EAE Models)
- Th17 differentiation inhibition + Treg preservation
- ↓ IL-17, ↓ IFN-gamma, preserved Foxp3+ Tregs
- 40% lower disease severity + reduced demyelination
- VIP modulates pathogenic T cell subsets without global immunosuppression. Critical for CNS autoimmunity